Thomas J Schall

Summary

Publications

  1. pmc A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development
    Jennifer M Burns
    ChemoCentryx, Inc, Mountain View, CA 94043, USA
    J Exp Med 203:2201-13. 2006
  2. doi request reprint Overcoming hurdles in developing successful drugs targeting chemokine receptors
    Thomas J Schall
    ChemoCentryx, Inc, 850 Maude Avenue, Mountain View, California 94043, USA
    Nat Rev Immunol 11:355-63. 2011
  3. ncbi request reprint Proinflammatory proteases liberate a discrete high-affinity functional FPRL1 (CCR12) ligand from CCL23
    Zhenhua Miao
    ChemoCentryx, Mountain View, CA 94043, USA
    J Immunol 178:7395-404. 2007
  4. doi request reprint Endothelial expression of CXCR7 and the regulation of systemic CXCL12 levels
    Robert D Berahovich
    ChemoCentryx, Inc, Mountain View, CA, USA
    Immunology 141:111-22. 2014
  5. doi request reprint Experimental evidence for the use of CCR2 antagonists in the treatment of type 2 diabetes
    Timothy J Sullivan
    ChemoCentryx, Inc, Mountain View, CA 94043, USA
    Metabolism 62:1623-32. 2013
  6. doi request reprint Elucidation of CXCR7-mediated signaling events and inhibition of CXCR4-mediated tumor cell transendothelial migration by CXCR7 ligands
    Brian A Zabel
    ChemoCentryx, Mountain View, CA 94043, USA
    J Immunol 183:3204-11. 2009
  7. doi request reprint CCR2 antagonist CCX140-B provides renal and glycemic benefits in diabetic transgenic human CCR2 knockin mice
    Timothy Sullivan
    850 Maude Ave, Mountain View, CA 94043
    Am J Physiol Renal Physiol 305:F1288-97. 2013
  8. doi request reprint CXCR7 protein is not expressed on human or mouse leukocytes
    Robert D Berahovich
    ChemoCentryx, Inc, Mountain View, CA 94043, USA
    J Immunol 185:5130-9. 2010
  9. pmc The novel chemokine receptor CXCR7 regulates trans-endothelial migration of cancer cells
    Brian A Zabel
    ChemoCentryx, Inc, 850 Maude Avenue, Mountain View, CA 94043, USA
    Mol Cancer 10:73. 2011
  10. pmc CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease
    Daniel J Dairaghi
    ChemoCentryx Inc, 850 Maude Ave, Mountain View, CA 94043, USA
    Blood 120:1449-57. 2012

Collaborators

Detail Information

Publications17

  1. pmc A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development
    Jennifer M Burns
    ChemoCentryx, Inc, Mountain View, CA 94043, USA
    J Exp Med 203:2201-13. 2006
    ....
  2. doi request reprint Overcoming hurdles in developing successful drugs targeting chemokine receptors
    Thomas J Schall
    ChemoCentryx, Inc, 850 Maude Avenue, Mountain View, California 94043, USA
    Nat Rev Immunol 11:355-63. 2011
    ..We highlight evidence suggesting that chemokine receptor inhibition will prove to be an effective therapy in inflammatory diseases...
  3. ncbi request reprint Proinflammatory proteases liberate a discrete high-affinity functional FPRL1 (CCR12) ligand from CCL23
    Zhenhua Miao
    ChemoCentryx, Mountain View, CA 94043, USA
    J Immunol 178:7395-404. 2007
    ..The sequential activation of a transient FPRL1 ligand and a longer-lived CCR1 ligand within a single chemokine may have important consequences for the development of inflammation or the link between innate and adaptive immunity...
  4. doi request reprint Endothelial expression of CXCR7 and the regulation of systemic CXCL12 levels
    Robert D Berahovich
    ChemoCentryx, Inc, Mountain View, CA, USA
    Immunology 141:111-22. 2014
    ..These studies suggest that endothelial CXCR7 regulates circulating CXCL12 levels and that CXCR7 inhibitors might be used to block CXCL12-mediated cell migration for therapeutic purposes. ..
  5. doi request reprint Experimental evidence for the use of CCR2 antagonists in the treatment of type 2 diabetes
    Timothy J Sullivan
    ChemoCentryx, Inc, Mountain View, CA 94043, USA
    Metabolism 62:1623-32. 2013
    ..The aim of this study was to provide a broad analysis of the various physiological changes occurring in mouse models of T2D in connection with pharmacological CCR2 inhibition...
  6. doi request reprint Elucidation of CXCR7-mediated signaling events and inhibition of CXCR4-mediated tumor cell transendothelial migration by CXCR7 ligands
    Brian A Zabel
    ChemoCentryx, Mountain View, CA 94043, USA
    J Immunol 183:3204-11. 2009
    ..CXCR7 ligands, such as the chemokine CXCL11 and the newly described synthetic molecule CCX771, may represent novel therapeutic opportunities for the control of such cells...
  7. doi request reprint CCR2 antagonist CCX140-B provides renal and glycemic benefits in diabetic transgenic human CCR2 knockin mice
    Timothy Sullivan
    850 Maude Ave, Mountain View, CA 94043
    Am J Physiol Renal Physiol 305:F1288-97. 2013
    ..These results support the ongoing evaluation of this molecule in diabetic subjects with impaired renal function...
  8. doi request reprint CXCR7 protein is not expressed on human or mouse leukocytes
    Robert D Berahovich
    ChemoCentryx, Inc, Mountain View, CA 94043, USA
    J Immunol 185:5130-9. 2010
    ..These studies therefore suggest that, whereas CXCR7 protein is expressed by primitive RBCs during murine embryonic development, in adult mammals CXCR7 protein is not expressed by normal peripheral blood cells...
  9. pmc The novel chemokine receptor CXCR7 regulates trans-endothelial migration of cancer cells
    Brian A Zabel
    ChemoCentryx, Inc, 850 Maude Avenue, Mountain View, CA 94043, USA
    Mol Cancer 10:73. 2011
    ..In this study, we set out to assess the potential stimulation by CXCL12 of tumor cell TEM towards other chemokines and whether CXCR7 might be able to regulate such effects...
  10. pmc CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease
    Daniel J Dairaghi
    ChemoCentryx Inc, 850 Maude Ave, Mountain View, CA 94043, USA
    Blood 120:1449-57. 2012
    ..These results provide a strong rationale for further development of CCR1 antagonists for the treatment of MM and associated osteolytic bone disease...
  11. pmc CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature
    Zhenhua Miao
    ChemoCentryx, Inc, Mountain View, CA 94043, USA
    Proc Natl Acad Sci U S A 104:15735-40. 2007
    ..Taken together, these data suggest that CXCR7 has key functions in promoting tumor development and progression...
  12. doi request reprint CCR9 inhibition does not interfere with the development of immune tolerance to oral antigens
    Matthew J Walters
    ChemoCentryx, Inc, 850 Maude Avenue, Mountain View, CA 94043, United States
    Immunol Lett 151:44-7. 2013
    ..These results highlight the inadequacy of genetic deletion of CCR9 when predicting the effects of pharmacological CCR9 inhibition on intestinal biology...
  13. doi request reprint Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease
    Matthew J Walters
    ChemoCentryx, Inc, Mountain View, CA 94043, USA
    J Pharmacol Exp Ther 335:61-9. 2010
    ..Analysis of the plasma level of drug associated with this improvement provides an understanding of the pharmacokinetic/pharmacodynamic relationship for CCR9 antagonists in the treatment of intestinal inflammation...
  14. ncbi request reprint Proteolytic activation of alternative CCR1 ligands in inflammation
    Robert D Berahovich
    ChemoCentryx, Mountain View, CA 94043, USA
    J Immunol 174:7341-51. 2005
    ..These data suggest that alternative CCR1 ligands are converted into potent chemoattractants by proteases released during inflammatory responses in vivo...
  15. pmc Potent immunosuppressive activities of cytomegalovirus-encoded interleukin-10
    Juliet V Spencer
    ChemoCentryx, San Carlos, California 94070, USA
    J Virol 76:1285-92. 2002
    ..These results demonstrate for the first time that CMV has a biologically active IL-10 homolog that may contribute to immune evasion during virus infection...
  16. ncbi request reprint Evidence for NK cell subsets based on chemokine receptor expression
    Robert D Berahovich
    ChemoCentryx, 850 Maude Avenue, Mountain View, CA 94043, USA
    J Immunol 177:7833-40. 2006
    ..These results indicate that within both the CD56(bright) and CD56(dim) NK cell populations, subsets with the capacity for differential trafficking programs exist, which likely influence their functions in innate and adaptive immunity...
  17. ncbi request reprint Comprehensive mapping of poxvirus vCCI chemokine-binding protein. Expanded range of ligand interactions and unusual dissociation kinetics
    Jennifer M Burns
    Division of Discovery Biology and Molecular Pharmacology, ChemoCentryx, San Carlos, California 94070, USA
    J Biol Chem 277:2785-9. 2002
    ..The determination of the binding fingerprint and unusual binding interactions of vCCI with a large number of chemokines suggest a finely honed evolutionary strategy of chemokine sequestration during viral infection...